Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Support

This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

Advances In™ PAH Associated with Congenital Heart Disease (PAH-CHD): Designing New Treatment Strategies Backed by Better Disease Understanding

Release Date: September 30, 2021
Expiration Date: September 30, 2022

Activity Overview

Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is a lethal and progressive disease in which prostacyclin, nitric oxide, and endothelin-1 pathways are disturbed and contribute to the pathophysiology of this disease. Undiagnosed or delayed diagnosis of PAH might lead to Eisenmenger syndrome (ES). Screening for PAH in patients with CHD and timely diagnosis can facilitate prompt treatment; promising medical therapies have recently been approved for the management of patients with PAH-CHD, bringing about hope for improved hemodynamics, exercise capacity, quality of life, and possibly, survival for this patient population.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This online educational activity is directed toward cardiologists, pulmonologists, NPs, PAs, and RNs. Additional healthcare professionals involved in the management and treatment of patients with PAH-CHD will also be invited to participate in this activity.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the latest theories of PAH-CHD pathogenesis
  • Discuss advances in the diagnostic and prognostic assessment of PAH-CHD
  • Determine appropriate treatment strategies for individual patients based on disease pathophysiology, disease severity, and risk assessments

Faculty, Staff, and Plannrs’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities


Richard Channick, MD
Richard Channick, MD
Professor of Medicine
UCLA David Geffen School of Medicine
Co-Director, Pulmonary Vascular Disease Program
UCLA Medical Center
Los Angeles, CA

Disclosures: Grant/Research Support: Janssen, Gossamer Bio; Consultant: Janssen, Bayer, Third Pole Therapeutics, Gossamer Bio, United Therapeutics; Speaker's Bureau: Janssen, Bayer

Vallerie McLaughlin, MD
Vallerie McLaughlin, MD
Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine
Associate Chief Clinic Officer, Cardiovascular Service Line, UMMG
Associate Chief, Division of Cardiovascular Medicine
Director, Inpatient Services
Director, Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI

Disclosures: Grant/Research Support: Acceleron, Janssen, Sanofi, United Therapeutics; Consultant: Acceleron, Aerovate Therapeutics, Altavant, Bayer, Caremark, CiVi BioPharma Inc., CorVista Health, Gossamer Bio, Janssen, Merck, United Therapeutics

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By